Abstract
Efficacy and tolerability of brexpiprazole – a new antipsychotic drug from the group of dopamine D2 receptor partial agonists
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have